Osilodrostat (LCI699)

Description:  Osilodrostat (LCI699; LCI-699; Isturisa) is a novel and potent inhibitor of 11β-hydroxylase and approved medication for the treatment of adults with Cushing's disease. Osilodrostat inhibits 11β-hydroxylase which is an enzyme catalyzing the final step of cortisol biosynthesis, thus can be used for all forms of Cushing's syndrome for patients who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Current evidence indicates that the novel aldosterone inhibitor LCI699 is an effective and well-tolerated antihypertensive agent that lowers plasma aldosterone concentration and produces a mild ACTH-stimulated cortisol response suppressive effect.